Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-04
2007-09-04
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C514S002600
Reexamination Certificate
active
10227185
ABSTRACT:
Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163. Accordingly, the KGF polypeptides of the present invention may be used in compositions in lesser amounts than would be necessary using KGF163.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5654405 (1997-08-01), Rubin et al.
patent: 5665870 (1997-09-01), Rubin et al.
patent: 5677278 (1997-10-01), Gospodarowicz et al.
patent: 5707805 (1998-01-01), Rubin et al.
patent: 5731170 (1998-03-01), Rubin et al.
patent: 5741642 (1998-04-01), Rubin et al.
patent: 5773586 (1998-06-01), Gospodarowicz et al.
patent: 5814605 (1998-09-01), Pierce et al.
patent: 5824643 (1998-10-01), Pierce et al.
patent: 5843883 (1998-12-01), Gospodarowicz et al.
patent: 5863767 (1999-01-01), Gospodarowicz et al.
patent: 5965530 (1999-10-01), Pierce et al.
patent: 6074848 (2000-06-01), Gospodarowicz et al.
patent: 1 334 981 (2003-08-01), None
patent: WO90/08771 (1990-08-01), None
patent: WO95/01434 (1995-01-01), None
patent: WO96/11949 (1996-04-01), None
patent: WO96/11951 (1996-04-01), None
patent: WO96/11952 (1996-04-01), None
patent: WO9611949 (1996-04-01), None
patent: WO98/24813 (1998-06-01), None
Bare et al., 1994, Biochem. Biophys. Res. Commun., vol. 205, pp. 872-879.
Ornitz and Itoh, 2001, Genome Biology, vol. 2(3), pp. 1-12.
Osslund, et al., Protein Science, 1998, vol. 7, pp. 1681-1690.
Nybo, et al., In Vitro Cellular and Developmental Biology: Animal, 1997, vol. 33(8), pp. 606-607.
Nybo et al., Letter to the Editor “Mitogenic Activity of Keratinocyte Growth Factor Amino-Terminal Truncation Mutants: Deletion of Amino Acid Residues 1-15 Through 1-27”, In Vitro Cell Dev. Biol., Animal 33:606-607 (1997).
Rubin et al., “Purification and Characterization of a Newly Identified Growth Factor Specific for Epithelial Cells”, Proc. Natl. Acad. Sci. USA, 86:802-806 (1989).
Baird et al., “Receptor-and Heparin-Binding Domains of Basic Fibroblast Growth Factor,”Proc. Natl. Acad. Sci. U.S.A. 85:2324-2328 (1988).
Basilico et al., “The FGF family of growth factors and oncogenes,”Adv. Cancer Res. 59:115-165 (1992).
Bellosta et al., “Cleavage of K-FGF produces a truncated molecule with increased biological activity and receptor binding affinity,”J. Cell Biol. 121(3):705-713 (1993).
Benjamin et al., “A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF,”Development 125:1591-1598 (1998).
Bowie et al., “Deciphering the message in protein sequences tolerance to amino acid substitutions,”Science 247:1306-1310 (1990).
Burgess et al., “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,”Anan. Rev. Biochem. 58:575-605 (1989).
Curti, “Physical barriers to drug delivery in tumors,”Critical Reviews in Oncology/Hematology 14:29-39 (1993).
Eriksson et al., “Three-Dimensional Structure of Human Basic Fibroblast Growth Factor,”Proc. Natl. Acad. Sci. U.S.A. 88:3441-3445 (1991).
Finch et al., “Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth,”Science 245:752-755 (1989).
Gospodarowicz et al., “Comparison of the Ability of Basic and Acidic Fibroblast Growth Factor to Stimulate the Proliferation of an Established Keratinocyte Cell Line: Modulation of Their Biological Effects by Heparin, Transforming Growth Factor β (TGFβ), and Epidermal Growth Factor (EGF),”Journal of Cellular Physiology 142:325-333 (1990).
Gospodarowicz et al., “Fibroblast growth factors: from genes to clinical applications,”Cell. Biol. Rev. 25:307-314 (1991).
Harper et al., “Reductive Methylation of Lysine Residues in Acidic Fibroblast Growth Factor: Effect on Mitogenic Activity and Heparin Affinity,”Biochemistry 27:671-678 (1988).
Jain, “Barriers to drug delivery in solid tumors,”Scientific American 271:58-65 (1994).
Massague, “The TGF- family of growth and differentiation factors,”Cell 49:437-438 (1987).
Meyer-Ingold “Wound therapy: growth factors as agents to promote healing,”Tibtech 11:387-392 (1993).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal paradox,” inThe Protein Folding Problem and Tertary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 491-495 (1994).
Osslund et al., “Correlation Between the 1.6 A Crystal Structure and Mutational Analysis of Keratinocyte Growth Factor,”Protein Science 7:1681-1690 (1998).
Pilbeam et al., “Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture,”Bone 14:717-720 (1993).
Powers et al., “Fibroblast growth factors, their receptors and signaling,”Endocrine-Related Cancer 7:165-197 (2000).
Reich-Slotky et al., “Chimeric Molecules Between Keratinocyte Growth Factor and Basic Fibroblast Growth Factor Define Domains that Confer Receptor Binding Specificities,”The Journal of Biological Chemistry 270(50):29813-29818.
Robinson, “Growth factors in wound healing,”Tibtec10:1-2 (1992).
Ron et al. “Expression of biologically active recombinant keratinocyte growth factor,”J. Biol Chem. 268(4):2984-2988 (1993).
Vukicevic et al., “Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7),”PNAS USA 93:9021-9026 (1996).
Wells, “Additivity of mutational effects in proteins,”Biochemistry 29:8509-8517 (1990).
Crawford Kenneth
Gospodarowicz Denis J.
Kavanaugh W. Michael
Abrahamson Susan L.
Chiron Corporation
Harbin Alisa A.
O'Hara Eileen B.
Robins Roberta L.
LandOfFree
KGF polypeptide compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with KGF polypeptide compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and KGF polypeptide compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3783033